The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S； R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S； and R2 is a cyclic group substituted at the α-position with a monovalent heterocyclic 10 group or a monovalent aromatic group, wherein a ring atom of the heterocyclic or aromatic group is directly attached to the α ring atom of the cyclic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
